Evaluating of pencil beam convolution and anisotropic analytical algorithms in stereotactic lung irradiation

Tania De La Fuente Herman, Kerry Hibbitts, Terence Herman, Salahuddin Ahmad
Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

ABSTRACT

The aim of this study was to evaluate differences in dose distributions in stereotactic body radiation therapy treatment plans for lung tumors calculated with pencil beam convolution (PBC) algorithm with modified Batho power law (MBPL) versus heterogeneity corrected anisotropic analytical algorithm (AAA) of the Varian Eclipse treatment planning system. The four-dimensional computed tomography images from 20 patients with lung cancer were used to create treatment plans. Plans used five to seven nonopposing coplanar 6 MV beams. Plans generated with the PBC algorithm and MBPL for tissue heterogeneity corrections were optimized to deliver 60 Gy in three fractions to at least 95% of the planned target volume, and the normal tissue doses for spinal cord, esophagus, heart, and ipsilateral bronchus were restricted to less than 18, 27, 30, and 30 Gy, respectively. Plans were recalculated with AAA, retaining identical beam arrangements, photon beam fluences, and monitor units. The pencil beam plans, designed to deliver 60 Gy, delivered on average 51.6 Gy when re-calculated with the AAA, suggesting a reduction of at least 10% to prescription dose is appropriate when calculating with the AAA.

Key words: Anisotropic analytical algorithm, dose calculation algorithm, lung cancer, pencil beam convolution

Introduction

Stereotactic body radiation therapy (SBRT) uses highly conformal techniques to deliver ablative radiation doses in few fractions to the tumor while limiting the doses received by the surrounding organs at risk (OARs).[1,2] The computed tomographic reconstruction correlated with respiratory motion (4D CT) allows the creation of treatment plans with smaller safety margins for patients with thoracic tumors, since the volumetric range of the tumor movement due to breathing is encompassed in the internal target volume (ITV) used for planning. When using a highly conformal radiation treatment for lung cancer, a therapeutic advantage may be achieved if the media heterogeneities in the path of the photon beam are incorporated when calculating an optimized treatment plan. Calculation algorithms have been incorporated into the treatment planning software to account for contributions from tissues of different densities that are near, far, and enclosing the site of interest. The heterogeneity corrections in the pencil beam model are based on dose values calculated in a water equivalent material multiplied by a heterogeneity correction factor generated from an electron density matrix derived from a CT value matrix.[3] The AAPM Task Group 65 reported the observations by many investigators who demonstrated experimentally or by theoretical analysis that the pencil-beam convolution algorithm (path length based) does not work in regions of electron disequilibrium, and compute incorrect doses within or near to a low density medium, particularly when the field size is small.[4] When creating SBRT treatment plans, the recently published, AAPM Task Group 101 report recommends the utilization of algorithms that account for 3D scatter integration such as convolution/superposition, and algorithms that account for better photon and electron transport such as Monte Carlo.[5]

The anisotropic analytical algorithm (AAA) is a pencil beam superposition-convolution algorithm for dose calculations,[6,8] available in the Eclipse treatment planning software from Varian Medical Systems (Palo Alto, CA), that has shown good accuracy overall and a great ability to handle...
small fields in inhomogeneous media.\textsuperscript{[9]} Dose distributions calculated by the AAA algorithm have been studied by several investigators\textsuperscript{[10-12]} and in the heterogeneous media; the AAA algorithm has been shown to be consistently more accurate than pencil beam convolution (PBC).\textsuperscript{[11,12]} Fotina \textit{et al.} compared the collapsed cone convolution (CCC) algorithm (Oncentra Masterplan), the AAA algorithm (Eclipse, Varian), and XVMC Monte Carlo algorithm (iPlan and Monaco), and showed that all these treatment planning systems performed accurate dose calculations in homogeneous and heterogeneous phantoms.\textsuperscript{[13]} Recently, authors in a paper on the accuracy of dose calculations by the AAA algorithm for stereotactic radiotherapy in nasopharyngeal carcinoma concluded that the results from the AAA were much better than those calculated by the PBC algorithm.\textsuperscript{[14]}

We performed this retrospective study looking at patients treated with PBC modified batho power law (MBPL) dose calculation algorithm in our institution. We are currently introducing AAA treatment planning in our clinic. The purpose of this study has been to judge the effect the choice of calculation algorithm (PBC or AAA) has on dose distribution and how this choice might affect patient treatment planning in terms of prescribing equivalent doses.

\textbf{Materials and Methods}

\textbf{Patients}

The subjects of this retrospective study were 20 patients with non-small cell lung cancer (NSCLC) treated with SBRT in the department of radiation oncology at our institution. The average age of this group of patients was 71.5 years (range, 58-85 years). All the patients were allowed to breathe freely, and the full breathing cycle was divided into ten phases. The real time position management (RPM) respiratory gating system version 1.6.5 (Varian Medical Systems, Palo Alto, CA) was employed during the CT scanning (GE LightSpeed CT Scanner) to create the 4D CT images that were sorted and transferred to the planning software using the GE Advantage Workstation aw4.3_06.

\textbf{Treatment planning}

The algorithms used for treatment planning were version 8.6.15 from Eclipse External Beam Treatment Planning (Varian Medical Systems, Palo Alto, CA). The plans used five to seven fields of non-opposing coplanar 6 MV beams. The ITVVs were delineated based on the average of all ten 4D CT images acquired during the full breathing cycle and given an extended margin of 0.7 cm to create the planning target volumes (PTVs). The plans were first generated with PBC utilizing MBPL for tissue heterogeneity correction and optimized to deliver a prescribed dose of 60 Gy in three fractions to at least 95% of the PTV, keeping the normal tissue doses for spinal cord, esophagus, heart, and ipsilateral bronchus limited to not more than 18, 27, 30, and 30 Gy, respectively, as recommended in RTOG 0236.\textsuperscript{[15]} For the normal lung, the percentage volume receiving 20 Gy or more, \(V_{20Gy}\) was restricted to 10%, unless this proved unworkable, in which case up to 15% was acceptable. Because radiation pneumonitis is volume- and dose-dependent, dose volume parameters such as \(V_{10Gy}\), \(V_{20Gy}\), \(V_{30Gy}\) \(V_{10 Gy}\), \(V_{20 Gy}\), and \(V_{30 Gy}\) representing the percent volumes of uninvolved lung tissue receiving doses above 10, 20 and 30 Gy, respectively, mean and maximum lung doses (MLD and MaxLD) were calculated to better quantify this relationship. The calculation grid resolution applied in the treatment planning software was 2.5 mm. The previously optimized treatment plans\textsuperscript{[16]} were then re-calculated with AAA using identical beam arrangements, photon beam fluences, and monitor units. The plans calculated with PBC MBPL were used as the standard for the purpose of comparisons and the percent differences in values were calculated.

\textbf{Results}

The minimum, maximum, and mean doses to the PTV calculated using PBC and AAA for all 20 patients are shown in Table 1. The AAA plans had significantly lower average minimum, mean, and maximum PTV doses by 16.6%, 8.2% and 2.1%, respectively, compared to those with PBC plans. Transversal CT images of a typical patient are shown in Figure 1. Figure 1(a) shows the ITV and PTV contours of a typical NSCLC patient, Figure 1(b) shows isodose distributions ranging from 53 Gy to 63 Gy in increments of 2 Gy calculated with PBC, and Figure 1(c) shows the same range of isodoses calculated with AAA. The dose volume histograms (DVHs) for PBC and AAA corresponding to this patient are shown in Figure 2.

Doses to the 95% of PTV \((D_{95})\) calculated using PBC and AAA for all 20 patients are shown in Table 2. The average dose to \(D_{95}\) calculated for the entire patient group with AAA was significantly lower by about 14% compared to that with PBC.

The average MLD, average MaxLD, \(V_{10Gy}\), \(V_{20Gy}\), and \(V_{30Gy}\), from all 20 patients are shown in Table 3. The AAA plans also had lower average mean and maximum doses to the uninvolved lung by 8.6% and 8.9%, respectively. Also, the average \(V_{10 Gy}\), \(V_{20 Gy}\), and \(V_{30 Gy}\) were below 10.2%, 5.2%, and 3.0% for both PBC and AAA plans, with AAA resulting in less calculated dose to the uninvolved lung.

\textbf{Discussion}

SBRT was implemented in 2006 in our clinic. Since it is a relatively new technique, for which precision and conformality are essential, this study has been a part of an effort to improve this implementation, and therefore,
Table 1: Minimum, maximum, and mean doses (in Gy) to PTV calculated with PBC and AAA for all 20 patients

| Patient | Minimum dose (Gy) | Maximum dose (Gy) | Mean dose (Gy) |
|---------|-------------------|-------------------|----------------|
|         | PBC | AAA | PBC | AAA | PBC | AAA |
| 1       | 54.86 | 44.76 | 68.13 | 67.65 | 64.43 | 58.36 |
| 2       | 56.51 | 44.08 | 66.24 | 60.04 | 63.56 | 53.61 |
| 3       | 40.96 | 41.00 | 75.41 | 74.07 | 63.11 | 61.52 |
| 4       | 56.36 | 54.68 | 65.83 | 65.74 | 63.11 | 62.38 |
| 5       | 55.81 | 46.49 | 64.95 | 65.41 | 62.48 | 60.13 |
| 6       | 52.91 | 40.25 | 67.07 | 66.76 | 63.24 | 58.31 |
| 7       | 50.56 | 43.72 | 68.73 | 67.81 | 64.72 | 59.52 |
| 8       | 55.26 | 47.05 | 67.27 | 66.49 | 63.76 | 60.67 |
| 9       | 54.30 | 40.00 | 67.63 | 66.89 | 63.69 | 54.93 |
| 10      | 54.84 | 41.35 | 68.88 | 66.12 | 63.29 | 55.95 |
| 11      | 55.83 | 44.66 | 66.12 | 66.24 | 62.99 | 60.28 |
| 12      | 52.91 | 41.26 | 68.81 | 66.83 | 64.38 | 56.48 |
| 13      | 57.03 | 49.97 | 65.54 | 65.34 | 62.89 | 60.62 |
| 14      | 39.77 | 39.50 | 73.36 | 74.00 | 64.26 | 60.81 |
| 15      | 56.72 | 47.01 | 65.71 | 62.93 | 62.68 | 57.99 |
| 16      | 54.26 | 44.14 | 66.80 | 64.27 | 64.01 | 56.75 |
| 17      | 54.58 | 46.25 | 67.03 | 65.99 | 63.96 | 60.07 |
| 18      | 53.01 | 42.80 | 68.74 | 68.43 | 64.53 | 59.54 |
| 19      | 54.34 | 43.70 | 67.11 | 64.43 | 63.99 | 57.60 |
| 20      | 56.27 | 43.21 | 67.24 | 62.46 | 63.48 | 53.25 |
| Average | 53.35 | 44.29 | 67.83 | 66.39 | 63.64 | 58.44 |

Table 2: Doses (in Gy) to the 95% PTV (D_{95}) calculated with PBC and AAA for all 20 patients

| Patient | PBC dose (Gy) | AAA dose (Gy) | % Difference |
|---------|---------------|---------------|--------------|
| 1       | 60.00 | 50.35 | 16.09 |
| 2       | 60.00 | 48.58 | 19.05 |
| 3       | 60.00 | 54.87 | 8.56 |
| 4       | 60.00 | 58.58 | 2.37 |
| 5       | 60.00 | 53.63 | 10.63 |
| 6       | 60.00 | 49.28 | 17.87 |
| 7       | 60.00 | 51.48 | 14.21 |
| 8       | 60.00 | 53.96 | 10.07 |
| 9       | 60.00 | 47.16 | 21.41 |
| 10      | 60.00 | 48.98 | 18.37 |
| 11      | 60.01 | 52.44 | 12.62 |
| 12      | 60.01 | 47.53 | 20.80 |
| 13      | 60.03 | 55.28 | 7.92 |
| 14      | 60.00 | 53.75 | 10.42 |
| 15      | 60.00 | 53.02 | 11.64 |
| 16      | 59.99 | 50.44 | 19.52 |
| 17      | 60.00 | 53.05 | 11.58 |
| 18      | 59.99 | 50.77 | 15.38 |
| 19      | 59.98 | 50.48 | 15.83 |
| 20      | 60.01 | 47.91 | 20.16 |
| Average | 60.00 | 51.58 | 14.04 |

Figure 1: (a) ITV and PTV contours of a typical NSCLC patient planned with SBRT. The six isodoses represent 53-63 Gy with increments of 2 Gy, and both views (b) PBC and (c) AAA (slightly magnified to display better the spread of isolines) are shown at the treatment plan isocenter.

maximize its therapeutic effect. Recent studies have demonstrated that the most appropriate treatment planning calculation algorithm for small lesions in the lung is the superposition-convolution algorithm.\[3\]
The RTOG 0236 protocol required that 95% of PTV be conformally covered by 60 Gy delivered in three fractions with no heterogeneity corrections applied. Xiao et al.\textsuperscript{[17]} reported on the recalculation of a subset of 20 treatment plans from RTOG 0236 with heterogeneity corrections using the superposition-convolution algorithm. They found that the average dose delivered to 95% of the PTV with no heterogeneity correction was 60.6 Gy, whereas with heterogeneity correction the average value dropped to 55.9 Gy. The authors advocated adjustment of the prescribed dose for future SBRT protocols that use accurate heterogeneity corrections. A prescribed dose of 18-19 Gy per fraction for three fractions, instead of 20 Gy per fraction for three fractions used in the RTOG 0236 protocol was recommended. In our study, the average dose to 95% of the PTV recalculation with AAA was 51.6 Gy for our group of 20 patients, whereas it was 60 Gy calculated with PBC (MBPL). Our work clearly suggests a prescription dose reduction of at least 10% (54 Gy instead of 60 Gy in three fractions) or even up to 14% (51.6 Gy instead of 60 Gy) when calculating dose with AAA instead of PBC with MBPL heterogeneity corrections.

Fragoso et al.\textsuperscript{[18]} also observed a marked reduction in calculated dose to the PTV when PBC-based plans were recalculated with the Monte Carlo (MC) based algorithm. The minimum PTV doses shown with the PBC and MC were 97% and 58%, respectively. The 80% and 95% isodose lines covering the ITV and PTV shown in a lung patient study, when calculated with PBC, did not encompass the PTV when recalculated with MC.\textsuperscript{[18]} A similar trend was also found in our study. In the DVHs shown in Figure 2, the minimum and mean doses to the PTV calculated with PBC (MBPL) were 56.3 Gy and 63.5 Gy, respectively, compared to 43.2 Gy and 53.3 Gy calculated with AAA; for this patient, the minimum and mean doses were overestimated by 30% and 19%, respectively. Also the isodose from 53 to 63 Gy did not cover the PTV in the AAA calculated plan as shown in Figure 1c.

Schuring and Hurkmans\textsuperscript{[19]} investigated the influence of inhomogeneity corrections on stereotactic treatment plans for NSCLC. They made treatment plans to deliver 60 Gy in three fractions using an equivalent path length (EPL) algorithm (like Batho), and calculated plans with the CCC algorithm. Their EPL plans overestimated the dose to 95% of the PTV, and, in one case, this overestimation was as high as 45%. In addition, their calculated $V_{10}$, $V_{20}$, and MLD using the CCC algorithm were significantly lower on average by 9.2%, 21.1% and 9.9%, respectively, compared to those using the EPL. In comparison, our $V_{10}$, $V_{20}$, and MLD were reduced by 5.8%, 10%, and 8.6% on average, respectively, when recalculated with AAA.

### Conclusion

The results from this study indicate that when creating SBRT treatment plans for lung lesions, the AAA algorithm, a scatter-based dose model with increased accuracy in scattered dose calculation, would be a more appropriate choice. If one decides to use the AAA dose calculation algorithm, the prescribed dose should be adjusted down by 10-14% in order to maintain equivalence to plans generated by the PBC algorithm with MBPL heterogeneity corrections. Our results are in excellent agreement with the recent suggestion by the quality assurance working group of the phase III Rosel study\textsuperscript{[20]} to reduce prescription dose from 20 Gy per fraction to 18 Gy per fraction in three fractions when utilizing AAA or CCC dose calculation models instead of PBC/MBPL.

### References

1. Timmernman R, McCarr R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-9.
2. Timmernman R, Kavanagh B, Chinoos Cho L, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 2007;25:947-52.
3. Carrasco P, Jornet N, Duch MA, Weber L, Ginjaume M, Eudaldo T, et al. Comparison of dose calculation algorithms in phantom with lung equivalent heterogeneities under conditions of lateral disequilibrium. Med Phys 2004;31:2899-911.
4. Papanikolaou N, Battista J, Boyer A, Kappas C, Klein E, Mackie TR,

---

**Table 3: Average doses (in Gy) of MLD, MaxLD, and the average percent volumes of uninvolved lung tissues $V_{10}$, $V_{20}$ and $V_{30}$ from all 20 patients**

|                  | PBC  | AAA  | Difference |
|------------------|------|------|------------|
| MLD (Gy)         | 3.59 | 3.28 | 6.84       |
| MaxLD (Gy)       | 64.37| 58.66| 8.87       |
| $V_{10}$ (%)     | 10.24| 9.65 | 0.60       |
| $V_{20}$ (%)     | 5.20 | 4.68 | 0.52       |
| $V_{30}$ (%)     | 3.01 | 2.46 | 0.55       |
et al. AAPM Report No. 85: Tissue inhomogeneity corrections for megavoltage photon beams: Report of Task Group No. 65 of the Radiation Therapy Committee of the American Association of Physicists in Medicine 2004.

5. Benedict SH, Yenice KM, Followill D, Calvin JM, Hinson W, Kavanaugh B, et al. Stereotactic body radiation therapy: The report of AAPM task group 101. Med Phys 2010;37:4078-101.

6. Ulmer W, Harder D. Applications of a triple gaussian pencil beam model for photon beam treatment planning. Med Phys 1996;6:68-74.

7. Sievinen J, Ulmers W, Kaisl W. AAA photon dose calculation model in eclipse. Varian RandD #7170B. Palo Alto, CA: Varian Medical Systems; 2005.

8. Fogliata A, Nicolini G, Vanetti E, Clivio A, Cozzi L. Dosimetric validation of the anisotropic analytical algorithm for photon dose calculation: Fundamental characterization in water. Phys Med Biol 2006;51:1421-38.

9. Sterpin E, Tomsej M, De Smedt B, Reyneart N, Vynckier S. AAPM task group 101. Med Phys 1996;6:68-74.

10. Cozzi L, Nicolini G, Vanetti E, Clivio A, Cozzi L. Basic dosimetric verification in water of the anisotropic analytical algorithm for Varian, Elekta and Siemens Linear accelerators. Z Med Phys 2008;18:126-35.

11. Bragg CM, Wingate K, Conway J. Clinical implications of the anisotropic analytical algorithm for IMRT treatment planning and verification. Radiother Oncol 2008;86:276-84.

12. Ronde HS, Hoffmann L. Validation of Varian’s AAA algorithm with focus on lung treatments. Acta Oncol 2009;48:209-15.

13. Fotina A, Winkler P, Künzler T, Reiterer J, Simmat I, Georg D. Advanced kernel methods vs Monte Carlo-based dose calculation for high energy photon beams. Radiother Oncol 2009;93:645-53.

14. Kan MW, Cheung JY, Leung LH, Lau BM, Yu PK. The accuracy of dose calculations by anisotropic analytical algorithms for stereotactic radiotherapy in nasopharyngeal carcinoma. Phys Med Biol 2011;56:397-413.

15. American College of Radiology. A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. Radiation Therapy Oncology Group, RTOG 0236; 2006. Philadelphia, PA: ACR; 2006.

16. de La Fuente Herman T, Vlachaki MT, Herman TS, Hibbits K, Stoner JA, Ahmad S. Stereotactic Body Radiation Therapy (SBRT) and respiratory gating in lung cancer: Dosimetric and radiobiological considerations. J Appl Clin Med Physics 2010;11:158-69.

17. Xiao Y, Papiez L, Paulus R, Timmerman R, Straube WL, Bosch WR, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: Stereotactic body radiation therapy of inoperable stage II non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2009;73:1235-42.

18. Fragoso M, Wen N, Kumar S, Liu D, Ryu S, Morsas B, et al. Dosimetric verification and clinical evaluation of a new commercially available Monte Carlo-based dose algorithm for application in Stereotactic Body Radiation Therapy (SBRT) treatment planning. Phys Med Biol 2010;55:4445-64.

19. Schuring D, Hurkmans CW. Developing and evaluating stereotactic lung RT trials: What We should know about the influence of inhomogeneity corrections on dose. Radiat Oncol 2008;3:21.

20. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Schuring D, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IIA non-small lung cancer: Report from the quality assurance working party of the randomised phase III ROSEL study. Radiat Oncol 2009;4:1.

How to cite this article: Herman TD, Hibbits K, Herman T, Ahmad S. Evaluation of pencil beam convolution and anisotropic analytical algorithms in stereotactic lung irradiation. J Med Phys 2011;36:234-8.

Source of Support: Nil, Conflict of Interest: None declared.